For Treatment of Invasive Aspergillosis, Posaconazole Was Noninferior to Voriconazole

In a randomized trial, mortality at 42 days was 15% with posaconazole and 21% with voriconazole.

Although voriconazole is recommended as a first-line treatment for patients with invasive pulmonary aspergillosis, its adverse event profile has prompted a search for alternatives. Posaconazole has been approved for preventing invasive fungal infections in susceptible hosts, but its efficacy in the treatment of invasive aspergillosis remains unclear; thus, researchers conducted a manufacturer-funded double-blind trial involving patients with proven, possible, or probable invasive aspergillosis. Participants were randomized to receive posaconazole or voriconazole; the primary outcome was all-cause mortality within 42 days.

Among 575 patients who received at least one dose of medication, 44 of 288 who received posaconazole (15%) and 59 of 287 …

Reviewing Author

Neil M. Ampel, MD

Disclosures

Editorial BoardsUpToDate

Leadership Positions in Professional SocietiesCoccidioidomycosis Study Group (Past President, Secretary, Treasurer)

Neil M. Ampel, MD

Disclosures

Editorial BoardsUpToDate

Leadership Positions in Professional SocietiesCoccidioidomycosis Study Group (Past President, Secretary, Treasurer)

For Treatment of Invasive Aspergillosis, Posaconazole Was Noninferior to Voriconazole

Topics

Reviewing Author